Article

A drug with few side effects can cure multiple ills

When I was a boy, my father mentioned several times how he might have purchased IBM stock decades earlier, and how much such an investment would have been worth at the time. Often, people tell me how they refrained from purchasing a waterfront home because the price seemed way too steep, only to have the value subsequently shoot up 10-fold. Perhaps we all regret not making certain purchases long ago.

Related Videos
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
Adam Wenick, MD, chairs EyeCon session: New treatments in geographic atrophy from detection to intervention
EyeCon 2024: Laura M. Periman, MD, shares her passion for dry eye disease, discussing her surprising discovery of the Alpenglow Sign in Demodex blepharitis
David Eichenbaum, MD, presents advances in AMD therapy, highlights different mechanisms with a common goal
Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Promising results for faricimab revealed in TENAYA, LUCERNE year 2 data
© 2024 MJH Life Sciences

All rights reserved.